Top

Published in:

01-10-2021 | Gastritis | Original Article

High-risk individuals for gastric cancer would be missed for surveillance without subtyping of intestinal metaplasia

Authors: Sergejs Isajevs, Selga Savcenko, Inta Liepniece-Karele, Maria Blanca Piazuelo, Ilze Kikuste, Ivars Tolmanis, Aigars Vanags, Indra Gulbe, Linda Mezmale, Darhan Samentaev, Altynbek Tazedinov, Ramis Samsutdinov, Tatjana Belihina, Nurbek Igissinov, Marcis Leja

Published in: Virchows Archiv | Issue 4/2021

Abstract

The use of Operative Link on Gastritis Assessment (OLGA) and Operative Link on Gastritis Assessment based on Intestinal Metaplasia (OLGIM) staging system is recommended for identifying subjects at risk for developing gastric cancer; usually high-risk lesions are considered only as stages III and IV. Accumulating evidence suggests that incomplete intestinal metaplasia (IM) is important in the development of gastric cancer. Our aim has been to identify the prevalence of incomplete IM in patients with low-risk OLGA/OLGIM stages among a high-risk general population. Healthy adult volunteers aged 40–64 years were invited to undergo upper endoscopy within a regional GISTAR pilot study in Kazakhstan (n = 166). Gastric lesions were staged according to OLGA/OLGIM staging system. High iron diamine–alcian blue (HID-AB) was used for subtyping IM. IM prevalence overall was 45.8%. Incomplete IM was present in 52.6% (type II in 30.3% and type III in 22.3%), whereas complete IM was found in 47.4% individuals. The prevalence of OLGIM I and II stage were 39.8 and 4.8%, respectively, whereas OLGIM III was observed in 1.2%. The prevalence of incomplete IM in patients stratified to OLGIM I was 54.5% (type II in 31.8% and type III in 22.7%). High prevalence of incomplete IM was detected not only in subjects with extensive IM, but in those stratified as at the OLGIM I stage. Without IM subtyping, patients with high risk of gastric cancer development would be missed for surveillance.

Pimentel-Nunes P, Libanio D, Marcos-Pinto R et al (2019) Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update. Endoscopy 51(4):365–388. https://doi.org/10.1055/a-0859-1883CrossRefPubMed

Gupta S, Li D, El Serag HB, Davitkov P, Altayar O, Sultan S, Falck-Ytter Y, Mustafa RA (2020) AGA clinical practice guidelines on management of gastric intestinal metaplasia. Gastroenterology 158(3):693–702. https://doi.org/10.1053/j.gastro.2019.12.003CrossRefPubMed

Rugge M, Capelle LG, Cappellesso R, Nitti D, Kuipers EJ (2013) Precancerous lesions in the stomach: from biology to clinical patient management. Best Pract Res Clin Gastroenterol 27(2):205–223. https://doi.org/10.1016/j.bpg.2012.12.007CrossRefPubMed

Rugge M, Correa P, Dixon MF, Fiocca R, Hattori T, Lechago J, Leandro G, Price AB, Sipponen P, Solcia E, Watanabe H, Genta RM (2002) Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Pharmacol Ther 16(7):1249–1259. https://doi.org/10.1046/j.1365-2036.2002.01301.xCrossRef

Cho SJ, Choi IJ, Kook MC, Nam BH, Kim CG, Lee JY, Ryu KW, Kim YW (2013) Staging of intestinal- and diffuse-type gastric cancers with the OLGA and OLGIM staging systems. Aliment Pharmacol Ther 38:1292–1302. https://doi.org/10.1111/apt.12515CrossRefPubMed

de Vries AC, van Grieken NCT, Looman CWN, Casparie MK, de Vries E, Meijer GA, Kuipers EJ (2008) Gastric cancer risk in patients with premalignant gastric lesions a nationwide cohort study in the Netherlands. Gastroenterology 134(4):945–952. https://doi.org/10.1053/j.gastro.2008.01.071CrossRefPubMed

de Vries AC, Haringsma J, de Vries RA, ter Borg F, Nagtzaam NM, Steyerberg EW, van Dekken H, Kuipers EJ (2009) The use of clinical, histologic, and serologic parameters to predict the intragastric extent of intestinal metaplasia: a recommendation for routine practice. Gastrointest Endosc 70:18–25. https://doi.org/10.1016/j.gie.2008.08.041CrossRefPubMed

Correa P, Piazuelo MB, Wilson KT (2010) Pathology of gastric intestinal metaplasia: clinical implications. Am J Gastroenterol 105(3):493–498. https://doi.org/10.1038/ajg.2009.728CrossRefPubMedPubMedCentral

Sonnenberg A, Lash RH, Genta RM (2010) A national study of Helicobactor pylori infection in gastric biopsy specimens. Gastroenterology 139(6):1894–1901. https://doi.org/10.1053/j.gastro.2010.08.018CrossRefPubMed

10.

Wong BC, Lam SK, Wong WM et al (2004) Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 291:187–194. https://doi.org/10.1001/jama.291.2.187CrossRefPubMed

11.

Tulassay Z, Stolte M, Engstrand L et al (2010) Twelve-month endoscopic and histological analysis following proton-pump inhibitor based triple therapy in Helicobacter pylori-positive patients with gastric ulcers. Scand J Gastroenterol 45:1048–1058CrossRef

12.

Yeh LY, Raj M, Hassan S, Aziz SA, Othman NH, Mutum SS, Naik VR (2009) Chronic atrophic antral gastritis and risk of metaplasia and dysplasia in an area with low prevalence of Helicobacter pylori. Indian J Gastroenterol 28:49–52CrossRef

13.

Isajevs S, Liepniece-Karele I, Janciauskas D, Moisejevs G, Putnins V, Funka K, Kikuste I, Vanags A, Tolmanis I, Leja M (2014) Gastritis staging interobserver agreement by applying OLGA and OLGIM systems. Virchows Arch 464(4):403–417. https://doi.org/10.1007/s00428-014-1544-3CrossRefPubMed

14.

Correa P, Haenszel W, Cuello C, Zavala D, Fontham E, Zarama G, Tannenbaum S, Collazos T, Ruiz B (1990) Gastric precancerous process in a high risk population: cross-sectional studies. Cancer Res 50:4731–4736PubMed

15.

Filipe MI, Munoz N, Matko I, Kato I, Pompe-Kirn V, Jutersek A, Teuchmann S, Benz M, Prijon T (1994) Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer 57:324–329CrossRef

16.

Shah SC, Gawron AJ, Mustafa RA, Piazuelo MB (2020) Histologic subtyping of gastric intestinal metaplasia: overview and considerations for clinical practice. Gastroenterology 158(3):745–750. https://doi.org/10.1053/j.gastro.2019.12.004CrossRefPubMed

17.

Gonzalez CA, Sanz-Anquela JM, Companioni O et al (2016) Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish follow-up study. J Gastroenterol Hepatol 31:953–958. https://doi.org/10.1111/jgh.13249CrossRefPubMed

18.

Song H, Ekheden IG, Zheng Z, Ericsson J, Nyrén O (2015) Ye W (2015) Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. BMJ 351:h3867. https://doi.org/10.1136/bmj.h3867CrossRefPubMedPubMedCentral

19.

Shichijo S, Hirata Y, Niikura R, Hayakawa Y, Yamada A, Ushiku T, Fukayama M, Koike K (2016) Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication. Gastrointest Endosc 84:618–624. https://doi.org/10.1016/j.gie.2016.03.791CrossRefPubMed

20.

Matsukauma A, Mori M (1990) Sulphomucin-secreting intestinal metaplasia in the human gastric mucosa. Cancer 66:689–694CrossRef

21.

You WC, Li JY, Blot WJ et al (1999) Evolution of precancerous lesions in a rural Chinese population at high risk of gastric cancer. Int J Cancer 83:615–619. https://doi.org/10.1002/(SICI)1097-0215(19991126)83:5%3c615::AID-IJC8%3e3.0.CO;2-L

22.

Filipe MI, Muñoz N, Matko I, Kato I, Pompe-Kirn V, Jutersek A, Teuchmann S, Benz M, Prijon T (1994) Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer 57:324–329. https://doi.org/10.1002/ijc.2910570306CrossRefPubMed

23.

Rokkas T, Filipe MI, Sladen GE (1991) Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. Gut 32:1110–1113. https://doi.org/10.1136/gut.32.10.1110CrossRefPubMedPubMedCentral

24.

Conchillo JM, Houben G, de Bruïne A, Stockbrügger R (2001) Is type III intestinal metaplasia an obligatory precancerous lesion in intestinal- type gastric carcinoma? Eur J Cancer Prev 10:307–312. https://doi.org/10.1097/00008469-200108000-00003CrossRefPubMed

25.

Kang KP, Lee HS, Kim N, Kang HM, Park YS, Lee DH, Choe G, Kim JS, Jung HC, Song IS (2009) Role of intestinal metaplasia subtyping in the risk of gastric cancer in Korea. J Gastroenterol Hepatol 24:140–148. https://doi.org/10.1111/j.1440-1746.2008.05546.xCrossRefPubMed

26.

González CA, Sanz-Anquela JM, Gisbert JP, Correa P (2013) Utility of subtyping intestinal metaplasia as marker of gastric cancer risk: a review of the evidence. Int J Cancer 133:1023–1032. https://doi.org/10.1002/ijc.28003CrossRefPubMed

27.

González CA, Pardo ML, Liso JM, Alonso P, Bonet C, Garcia RM, Sala N, Capella G, Sanz-Anquela JM (2010) Gastric cancer occurrence in preneoplastic lesions: a long-term follow-up in a high-risk area in Spain. Int J Cancer 127:2654–2660. https://doi.org/10.1002/ijc.25273CrossRefPubMed

28.

Dinis-Ribeiro M, Lopes C, da Costa-Pereira A, Guilherme M, Barbosa J, Lomba-Viana H, Silva R, Moreira-Dias L (2004) A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia. J Clin Pathol 57:177–182. https://doi.org/10.1136/jcp.2003.11270CrossRefPubMedPubMedCentral

29.

Lin CK, Lai KH, Lo GH, Cheng JS, Hsu PI, Mok KT, Tseng HH (2001) Cathepsin E and subtypes of intestinal metaplasia in carcinogenesis of the human stomach. Zhonghua Yi Xue Za Zhi 64:331–336PubMed

30.

Rokkas T, Sechopoulos P, Pistiolas D, Margantinis G, Koukoulis G (2010) Helicobacter pylori infection and gastric histology in first degree relatives of gastric cancer patients a meta-analysis. Eur J Gastroenterol Hepatol 22:1128–1133. https://doi.org/10.1097/MEG.0b013e3283398d37CrossRefPubMed

31.

Silva S, Filipe MI, Pinho A (1990) Variants of intestinal metaplasia in the evolution of chronic atrophic gastritis and gastric ulcer. A follow up study Gut 31:1097–1104. https://doi.org/10.1136/gut.31.10.1097CrossRefPubMed

32.

Gawron AJ, Shah SC, Altayar O, Davitkov P, Morgan D, Turner K, Mustafa RA (2020) AGA technical review on gastric intestinal metaplasia—natural history and clinical outcomes. Gastroenterology 158:709–735. https://doi.org/10.1053/j.gastro.2019.12.001CrossRef

33.

Umarova G, Mamyrbayev A, Bermagambetova S, Baspakova A, Satybaldieva U, Sabyrakhmetova V, Abilov T, Sultanova G, Uraz R (2016) Morbidity disability and death rates of the population due to malignant neoplasms in Uralsk city in the republic of Kazakhstan. Asian Pac J Cancer Prev 17(12):5159–5164. https://doi.org/10.22034/APJCP.2016.17.12.5159CrossRefPubMedPubMedCentral

34.

Leja M, Park JY, Murillo R, et al (2017) Multicentric randomised study of Helicobacter pylori eradication and pepsinogen testing for prevention of gastric cancer mortality: the GISTAR study. BMJ Open 11;7(8):e016999. https://doi.org/10.1136/bmjopen-2017-016999

35.

Mezmale L, Isajevs S, Bogdanova I et al (2019) Prevalence of atrophic gastritis in Kazakhstan and the accuracy of pepsinogen tests to detect gastric mucosal atrophy. Asian Pac J Cancer Prev 20(12):3825–3829. https://doi.org/10.31557/APJCP.2019.20.12.3825CrossRefPubMedPubMedCentral

36.

Mezmale L, Polaka I, Rudzite D et al (2021) Prevalence and potential risk factors of Helicobacter pylori infection among asymptomatic individuals in Kazakhstan. Asian Pac J Cancer Prev 22(2):597–602. https://doi.org/10.31557/APJCP.2021.22.2.597CrossRefPubMedPubMedCentral

37.

Kulmambetova GN, Imanbekova MK, Logvinenko AA, Sukashev AT, Filipenko ML, Ramanculov EM (2014) Association of cytokine gene polymorphisms with gastritis in a Kazakh population. Asian Pac J Cancer Prev 15:7763–7768CrossRef

38.

Benberin V, Bektayeva R, Karabayeva R, Lebedev A, Akemeyeva K, Paloheimo L, Syrjänen K (2013) Prevalence of H. pylori infection and atrophic gastritis among symptomatic and dyspeptic adults in Kazakhstan. A hospital-based screening study using a panel of serum biomarkers. Anticancer Res 33:4595–4602PubMed

39.

de Vries AC, Meijer GA, Looman CW, Casparie MK, Hansen BE, van Grieken NC, Kuipers EJ (2007) Epidemiological trends of pre-malignant gastric lesions: a long-term nationwide study in the Netherlands. Gut 56:1665–1670. https://doi.org/10.1136/gut.2007.127167CrossRefPubMedPubMedCentral

40.

Marques-Silva L, Areia M, Elvas L, Dinis-Ribeiro M (2014) Prevalence of gastric precancerous conditions: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 26:378–387. https://doi.org/10.1097/MEG.0000000000000065CrossRefPubMed

41.

Eriksson NK, Karkkainen PA, Farkkila MA, Arkkila PE (2008) Prevalence and distribution of gastric intestinal metaplasia and its subtypes. Dig Liver Dis 40:355–360. https://doi.org/10.1016/j.dld.2007.12.012CrossRefPubMed

42.

Ozdil K, Sahin A, Kahraman R, Yuzbasioglu B, Demirdag H, Calhan T, Yuzbasioglu B, Demirdag H, Calhan T, Muberra S, Yilmaz H, Sokmen M (2010) Current prevalence of intestinal metaplasia and Helicobacter pylori infection in dyspeptic adult patients from Turkey. Hepatogastroenterology 57:1563–1566PubMed

43.

Rugge M, Meggio A, Pravadelli C, Barbareschi M, Fassan M, Gentilini M, Zorzi M, De Pretis G, Graham DY, Genta RM (2019) Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients. Gut 68(1):11–17. https://doi.org/10.1136/gutjnl-2017-314600CrossRefPubMed

44.

Tava F, Luinetti O, Ghigna MR, AlvisiC PM, Trespi E, Klersy C, Fratti C, Fiocca R, Solcia E (2006) Type or extension of intestinal metaplasia and immature/atypical “indefinite-for dysplasia” lesions as predictors of gastric neoplasia. Hum Pathol 37:1489–1497. https://doi.org/10.1016/j.humpath.2006.05.012CrossRefPubMed

Title: High-risk individuals for gastric cancer would be missed for surveillance without subtyping of intestinal metaplasia
Authors: Sergejs Isajevs
Selga Savcenko
Inta Liepniece-Karele
Maria Blanca Piazuelo
Ilze Kikuste
Ivars Tolmanis
Aigars Vanags
Indra Gulbe
Linda Mezmale
Darhan Samentaev
Altynbek Tazedinov
Ramis Samsutdinov
Tatjana Belihina
Nurbek Igissinov
Marcis Leja
Publication date: 01-10-2021
Publisher: Springer Berlin Heidelberg
Keywords: Gastritis
Gastric Cancer
Gastric Cancer
Published in: Virchows Archiv / Issue 4/2021
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-021-03116-3

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

High-risk individuals for gastric cancer would be missed for surveillance without subtyping of intestinal metaplasia

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2021

Transbronchial biopsies’ histopathological findings leading to successful late steroid therapy in Covid-19 acute respiratory failure

Clear cell tumor with melanocytic differentiation and MITF-CREM translocation: a novel entity similar to clear cell sarcoma

Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2-positive breast cancer?

Postmodernism and the decline of the clinical autopsy

The role of molecular diagnostics in aneurysmal and simple bone cysts – a prospective analysis of 19 lesions

Correction to: 33rd European Congress of Pathology – Abstracts